Grace Therapeutics (GRCE) Price & Analysis

Compare

1,173 Followers

GRCE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.75 - $4.97

Previous CloseN/A

Volume30.96K

Average Volume (3M)87.86K

Market Cap

$42.73M

Enterprise Value$27.29M

Total Cash (Recent Filing)$20.00M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.01

Next Earnings

Nov 17, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding13,828,562

10 Day Avg. Volume66,474

30 Day Avg. Volume87,858

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.64

Enterprise Value/Revenue3.41K

Enterprise Value/Gross Profit27.29K

Enterprise Value/Ebitda-1.81

Forecast

1Y Price Target

$12.00

Price Target Upside288.35% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical ResultsIV GTx-104 has demonstrated bioequivalence to oral nimodipine, and the prospective, open-label, randomized Phase III STRIVE-ON safety study demonstrated numerically less clinically significant hypotension.

Market OpportunityGTx-104 represents a $300MM+ opportunity, with potential upside following real-world experience given KOL enthusiasm.

Product DevelopmentGTx-104 will be a welcome alternative treatment for aneurysmal subarachnoid hemorrhage.

Bears Say

Grace Therapeutics News

Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial

Grace Therapeutics (GRCE) announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH...

7d ago

GRCE

Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104

Grace Therapeutics (GRCE) announced that the U.S. Patent and Trademark Office has issued a U.S. Patent No. 12,414,943,...

11d ago

GRCE

Grace Therapeutics Secures New Patent for GTx-104

An update from Grace Therapeutics ( ($GRCE) ) is now available. On September 18, 2025, Grace Therapeutics announced...

11d ago

GRCE

Grace Therapeutics Holds Annual Stockholders Meeting

Grace Therapeutics ( ($GRCE) ) has shared an update. On September 12, 2025, Grace Therapeutics, Inc. held its...

16d ago

GRCE

FDA Accepts Grace Therapeutics’ NDA for GTx-104

Grace Therapeutics ( ($GRCE) ) has issued an update. On August 22, 2025, the FDA accepted Grace Therapeutics‘...

1M ago

GRCE

Grace Therapeutics announces U.S. FDA accepted NDA for GTx-104 for review

Grace Therapeutics (GRCE) announced that on August 22, 2025 the U.S. Food and Drug Administration, FDA, accepted the...

1M ago

GRCE

Grace Therapeutics Reports Q2 2025 Earnings and Strategic Focus

Acasti Pharma, Inc. ( ($GRCE) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

GRCE

Grace Therapeutics reports Q1 EPS (21c) vs (24c) last year

“During our first quarter of 2026 we continued to execute on our clinical and corporate goals, led by...

2M ago

GRCE

Grace Therapeutics management to meet virtually with Craig-Hallum

Virtual Meeting to be held on July 24 hosted by Craig-Hallum. Published first on TheFly – the ultimate...

2M ago

GRCE

Grace Therapeutics Submits New Drug Application to FDA

The latest announcement is out from Grace Therapeutics ( ($GRCE) ). On June 25, 2025, Grace Therapeutics announced...

3M ago

GRCE

Grace Therapeutics announces submission to U.S. FDA of NDA for GTx-104

Grace Therapeutics (GRCE) announced the submission to the U.S. Food and Drug Administration, FDA, of the Company’s New...

3M ago

GRCE

Grace Therapeutics Reports Promising Drug Development Progress

Acasti Pharma, Inc. ( ($GRCE) ) has released its Q4 earnings. Here is a breakdown of the information...

3M ago

GRCE

U.S. strikes Iran nuclear sites, Novo terminates Hims & Hers deal: Morning Buzz

The major averages were fractionally higher near noon even as the U.S. got involved in Israel’s war over...

3M ago

AMD

Grace Therapeutics reports FY25 EPS (79c), consensus ($1.66)

At March 31, 2025, the Company had cash and cash equivalents of $22.1 million, a net decrease of...

3M ago

GRCE

GRCE FAQ

What was Grace Therapeutics’s price range in the past 12 months?

Grace Therapeutics lowest stock price was $1.75 and its highest was $4.96 in the past 12 months.

What is Grace Therapeutics’s market cap?

Grace Therapeutics’s market cap is $42.73M.

When is Grace Therapeutics’s upcoming earnings report date?

Grace Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 49 days.

How were Grace Therapeutics’s earnings last quarter?

Grace Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.22 by $0.01.

Is Grace Therapeutics overvalued?

According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Grace Therapeutics pay dividends?

Grace Therapeutics does not currently pay dividends.

What is Grace Therapeutics’s EPS estimate?

Grace Therapeutics’s EPS estimate is -0.25.

How many shares outstanding does Grace Therapeutics have?

Grace Therapeutics has 13,828,562 shares outstanding.

What happened to Grace Therapeutics’s price movement after its last earnings report?

Grace Therapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.22. Following the earnings report the stock price went up 3.226%.

Which hedge fund is a major shareholder of Grace Therapeutics?

Currently, no hedge funds are holding shares in GRCE

Grace Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-16.78%

Trailing 12-Months

Asset Growth

0.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Grace Therapeutics

Grace Therapeutics (GRCE) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for rare and underserved diseases. The company operates within the healthcare sector, focusing on developing targeted treatments that address significant unmet medical needs. Grace Therapeutics leverages cutting-edge research and development capabilities to bring novel therapeutics to market, aiming to improve patient outcomes and quality of life.

Grace Therapeutics (GRCE) Earnings & Revenues

Historic Earnings Reports

GRCE Stock 12 Month Forecast

Average Price Target

$12.00

▲(288.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.683076923076923,4.376153846153846,5.069230769230769,5.762307692307692,6.455384615384615,7.148461538461539,7.841538461538462,8.534615384615385,9.227692307692308,9.920769230769231,10.613846153846154,11.306923076923077,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.683076923076923,4.376153846153846,5.069230769230769,5.762307692307692,6.455384615384615,7.148461538461539,7.841538461538462,8.534615384615385,9.227692307692308,9.920769230769231,10.613846153846154,11.306923076923077,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.683076923076923,4.376153846153846,5.069230769230769,5.762307692307692,6.455384615384615,7.148461538461539,7.841538461538462,8.534615384615385,9.227692307692308,9.920769230769231,10.613846153846154,11.306923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.73,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >